Countries by Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV)
Four countries — Botswana, Eswatini, Ireland, and Uganda — each achieve 100% antiretroviral therapy coverage for PMTCT, meaning every recorded pregnant woman living with HIV receives treatment to prevent mother-to-child transmission. At the other end, Sudan stands at 5%, the lowest among 82 countries with available data. The 95-percentage-point gap between the top and bottom of the ranking reflects the wide variation in how countries are reaching this population.
Ranking 2024
Values shown in %.
| Rank | Country | % |
|---|---|---|
| 1 | Botswana | 100.00 |
| 1 | Eswatini | 100.00 |
| 1 | Ireland | 100.00 |
| 1 | Uganda | 100.00 |
| 5 | Ghana | 99.00 |
| 5 | Malaysia | 99.00 |
| 5 | Rwanda | 99.00 |
| 5 | Tanzania | 99.00 |
| 9 | Bolivia | 98.00 |
| 9 | South Africa | 98.00 |
| 9 | Zambia | 98.00 |
| 12 | Cambodia | 97.00 |
| 12 | Eritrea | 97.00 |
| 12 | Namibia | 97.00 |
| 12 | Thailand | 97.00 |
| 16 | Malawi | 96.00 |
| 16 | Romania | 96.00 |
| 18 | Lesotho | 94.00 |
| 18 | Senegal | 94.00 |
| 20 | Sierra Leone | 93.00 |
| 20 | Zimbabwe | 93.00 |
| 22 | Ethiopia | 92.00 |
| 22 | Tajikistan | 92.00 |
| 24 | Peru | 91.00 |
| 25 | Armenia | 90.00 |
| 25 | Benin | 90.00 |
| 25 | Kenya | 90.00 |
| 25 | Kyrgyzstan | 90.00 |
| 29 | Cuba | 89.00 |
| 30 | Côte d'Ivoire | 88.00 |
| 30 | Liberia | 88.00 |
| 32 | Togo | 87.00 |
| 33 | Panama | 86.00 |
| 34 | Ecuador | 85.00 |
| 34 | Vietnam | 85.00 |
| 36 | Guyana | 84.00 |
| 37 | Guatemala | 82.00 |
| 37 | Mozambique | 82.00 |
| 39 | South Sudan | 81.00 |
| 40 | Cabo Verde | 80.00 |
| 40 | Guinea | 80.00 |
| 42 | Angola | 79.00 |
| 42 | Guinea-Bissau | 79.00 |
| 42 | Moldova | 79.00 |
| 45 | Chad | 77.00 |
| 45 | Gambia | 77.00 |
| 47 | Algeria | 74.00 |
| 48 | Gabon | 72.00 |
| 48 | Morocco | 72.00 |
| 50 | Libya | 70.00 |
| 51 | Burkina Faso | 69.00 |
| 51 | Central African Republic | 69.00 |
| 53 | Dominican Republic | 68.00 |
| 53 | Laos | 68.00 |
| 55 | El Salvador | 66.00 |
| 55 | Suriname | 66.00 |
| 57 | Burundi | 65.00 |
| 57 | Nepal | 65.00 |
| 59 | Niger | 63.00 |
| 60 | Haiti | 60.00 |
| 61 | Cameroon | 59.00 |
| 62 | Fiji | 57.00 |
| 63 | Myanmar | 54.00 |
| 64 | Colombia | 53.00 |
| 65 | Paraguay | 52.00 |
| 66 | Mali | 46.00 |
| 67 | Somalia | 43.00 |
| 68 | Republic of Congo | 42.00 |
| 68 | Costa Rica | 42.00 |
| 68 | Honduras | 42.00 |
| 71 | Mauritania | 39.00 |
| 72 | Djibouti | 38.00 |
| 73 | DR Congo | 32.00 |
| 73 | Tunisia | 32.00 |
| 75 | Madagascar | 30.00 |
| 76 | Papua New Guinea | 28.00 |
| 77 | Egypt | 27.00 |
| 78 | Philippines | 16.00 |
| 79 | Afghanistan | 14.00 |
| 79 | Pakistan | 14.00 |
| 81 | Yemen | 11.00 |
| 82 | Sudan | 5.00 |
Analysis
This metric measures the percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT). The unit is percentage, and higher values indicate broader coverage. Data comes from the World Bank World Development Indicators, indicator code SH.HIV.PMTC.ZS, for the reference year 2024. The dataset covers 82 countries, all with data from the last seven years, and 100% of datapoints are classified as official. No extreme outliers were detected using a 3-standard-deviation threshold. Values range from 5% to 100%, a spread of 1,900%. The metric captures medicine receipt only; it does not account for treatment adherence, dosage accuracy, or outcomes for mother or child.
At the top of the ranking, four countries share rank 1 with 100% coverage: Botswana, Eswatini, Ireland, and Uganda. They are followed closely by Ghana, Malaysia, Rwanda, and Tanzania, all at 99% (rank 5), and Bolivia, South Africa, and Zambia at 98% (rank 9). The top tier is geographically diverse, with sub-Saharan African countries, Southeast Asian countries, and European and Latin American countries all represented. Cambodia, Eritrea, Namibia, and Thailand each reach 97% (rank 12), and Malawi and Romania both reach 96% (rank 16).
Coverage drops more sharply in the lower half of the ranking. Colombia sits at 53% (rank 64), Paraguay at 52% (rank 65), and Mali at 46% (rank 66). The Democratic Republic of Congo and Tunisia both register 32% (rank 73), Madagascar reaches only 30% (rank 75), and Papua New Guinea 28% (rank 76). The Philippines records 16% (rank 78), Afghanistan and Pakistan both 14% (rank 79), Yemen 11% (rank 81), and Sudan 5% (rank 82). A notable anomaly appears in the middle of the ranking: Costa Rica and Honduras — both in Central America — appear at rank 68 with 42%, well below regional neighbors such as Panama at 86% (rank 33) and Guatemala at 82% (rank 37).
This metric has several limitations. It measures the proportion of pregnant women living with HIV who receive antiretroviral medicine, but the denominator — estimated pregnant women living with HIV — relies on modeled figures that vary in reliability by country. Countries with smaller HIV-positive pregnant populations may show extreme values, including 100%, based on small absolute numbers. Reporting practices differ across health systems, and some countries may undercount either the numerator or the denominator. The 93.9% consistency rate for 2024 means a small number of countries use data from earlier years, which may reduce strict comparability.
Methodology
The metric is defined as the percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT). Data are drawn from the World Bank World Development Indicators, indicator code SH.HIV.PMTC.ZS, with a reference year of 2024. The dataset includes 82 countries, all of which have data from within the last seven years (100% recency). All 82 datapoints are classified as official quality (100%). No extreme outliers were identified using a 3-standard-deviation threshold. The average year-over-year change across the dataset is 15.5%, well within the 50% volatility threshold. Values range from 5% (Sudan) to 100% (Botswana, Eswatini, Ireland, Uganda), representing a 1,900% spread. Coverage is reported as a percentage; the metric does not capture treatment adherence, clinical outcomes, or the absolute number of women receiving treatment.